Crucell Announces Acquisition of SBL Vaccin AB

23-Nov-2006

Crucell N.V. announced that it has signed an agreement for the acquisition of Stockholm-based SBL Vaccin AB (SBL) from 3i and SEB for a total consideration of EUR39.4 million in cash. It is expected that the acquistion will be completed on Thursday, November 23, 2006.

SBL is a fully integrated independent Swedish biotechnology company employing 120 people. SBL's main product is Dukoral®, an oral vaccine which offers protection against cholera and is registered in more than 50 countries excluding the US. Dukoral® is also registered in the same countries (excluding the EU and Australia) to protect against ETEC (travelers' diarrhea). Sales have increased by more than 60% since 2004. In 2005 sales exceeded EUR14 million (SEK 125 million).

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...